The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma

  title={The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma},
  author={Shin Ishihara and Takeshi Iwasaki and Kenichi Kohashi and Yuichi Yamada and Yu Toda and Yoshihiro Ito and Yousuke Susuki and Kengo Kawaguchi and Dai Takamatsu and Shinichiro Kawatoko and Daisuke Kiyozawa and Taro Mori and Izumi Kinoshita and Hidetaka Yamamoto and Toshifumi Fujiwara and Nokitaka Setsu and Makoto Endo and Yoshihiro Matsumoto and Yasuharu Nakashima and Yoshinao Oda},
  journal={Journal of Cancer Research and Clinical Oncology},
  pages={2003 - 2011}
Undifferentiated pleomorphic sarcoma (UPS) is a sarcoma with a poor prognosis. A clinical trial, SARC028, revealed that treatment with anti-PD-1 drugs was effective against UPS. Studies have reported that UPS expresses PD-L1, sometimes strongly (≥ 50%). However, the mechanism of PD-L1 expression in UPS has remained unclear. CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) was identified as a novel regulator of PD-L1 expression. The positive relationship between PD-L1 and CMTM6 has… 

Figures and Tables from this paper

Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas
The results suggest that an inducible immune checkpoint mechanism may be involved in UPS, MFS, and MPNST and the clinical features positively correlated with the positive PD-1/PD-L1 expression rates.
The clinical and prognostic significance of CMTM6/PD-L1 in oncology
The absence of a specific review article addressing the available results about the clinical and prognostic roles of CMTM6 alone and/or in combination with PD-L1 in cancer has encouraged us to write this paper.
CMTM Family and Gastrointestinal Tract Cancers: A Comprehensive Review
A systematic review of the latest advances of CMTM family’ roles in gastrointestinal tract cancers concludes that upregulated or downregulated expression of the family members was related to advanced tumor stage, metastasis, and overall survival.
Suppression of tumor/host intrinsic CMTM6 drives anti-tumor cytotoxicity in a PD-L1 independent manner
The findings reveal that both tumor and host CMTM6 are deeply involved in tumor immunity with or without the PD-1/PD-L1 axis and that gene therapy targeting C MTM6 is a promising strategy for cancer immunotherapy.


PD‑L1 and IDO‑1 expression in undifferentiated pleomorphic sarcoma: The associations with tumor infiltrating lymphocytes, dMMR and HLA class I.
It was suggested that PD‑L1 expression (≥50%) and IDO‑1 expression are poor and favorable prognostic factors of UPS patients, respectively.
Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients
CMTM6 expression can be a promising predictor useful for therapeutic decision-making regarding PD-1 inhibitors, and its association with PD-L1 has not been confirmed.
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab
The findings support that multiple cell types present at the start of treatment may enhance tumor regression following anti–PD-1 therapy in specific advanced sarcomas and show that quantitative assessments of CD8+ CD3+ PD-1+ T cells, percentage of TAMs expressing PD-L1, and other T-cell densities correlate with sarcoma response to pembrolizumab and improved PFS.
Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma
A new immune classification, based on CMTM6/PD-L1 coexpression and inflammatory cells, successfully stratified OS and DFS in MTM HCC patients, and is shown to be related to a high density of inflammatory cells.
CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients
CMTM6 expression is significantly related to PD-L1 and may be a useful prognostic indicator and a specific therapeutic target for cancer immunotherapy for GC patients.
Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy
High CMTM6 and PD-L1 co-expression in the stromal compartment was significantly associated with longer survival in treated patients and shows potential as a predictive factor for ICI treatments.
Quantitative assessment of CMTM6 in the tumor microenvironment and association with response to PD-1 pathway blockade in advanced-stage non-small-cell lung cancer.
  • J. Zugazagoitia, Yuting Liu, D. Rimm
  • Biology, Medicine
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2019
PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue – prognostic implications and rationale for immunotherapy
Findings represent novel insights into the immune landscape of soft tissue sarcomas, in particular UPS, and strengthen the rationale for immunotherapy, including targeting the PD-1/PD-L1 axis in these tumors.
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
The data reveal that PD-L1 relies on CMTM6/4 to efficiently carry out its inhibitory function, and suggest potential new avenues to block this pathway.
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Insight is provided into the biology of PD-L1 regulation, a previously unrecognized master regulator of this critical immune checkpoint is identified, and a potential therapeutic target to overcome immune evasion by tumour cells is highlighted.